Umpqua Bank bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 9,943 shares of the biopharmaceutical company's stock, valued at approximately $263,000.
Other hedge funds have also modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Stock Down 1.4 %
NYSE PFE traded down $0.36 during trading on Wednesday, reaching $25.19. 49,455,223 shares of the company's stock were exchanged, compared to its average volume of 36,737,476. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company's fifty day simple moving average is $26.14 and its 200-day simple moving average is $27.00. The firm has a market capitalization of $142.88 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 EPS. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Buying and Selling
In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on PFE shares. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.
View Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
